{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.1","value":"503"},{"groupId":"OG001","spread":"24.1","value":"449"},{"groupId":"OG002","spread":"26.4","value":"814"},{"groupId":"OG003","spread":"28.1","value":"511"},{"groupId":"OG004","spread":"15.5","value":"458"},{"groupId":"OG005","spread":"41.3","value":"601"},{"groupId":"OG006","spread":"31.3","value":"679"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"7"}],"units":"Participants"}],"description":"Serum concentrations of TTX-030 will be tabulated","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15, plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG000","title":"TTX-030 (Load+Q2W) + Budigalimab (Q4W) + mFOLFOX6 (Q2W)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus mFOLFOX6 over 48 hours (Q2W) on Day 1 and 15 of each 28-day cycle.","id":"OG001","title":"TTX-030 (Load+Q2W) + mFOLFOX6 (Q2W)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus docetaxel at a dose of 75 mg/m2 Q3W on Day 1 of each 21-day treatment cycle.","id":"OG002","title":"TTX-030 (Load+Q3W) + Budigalimab (Q3W) + Docetaxel (Q3W)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus budigalimab at a dose of 500 mg (Q4W) on Day 1 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG003","title":"TTX-030 (Load+Q2W) + Budigalimab (Q4W) + Gemcitabine + Nab-paclitaxel (Days 1, 8, 15)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 20 mg/kg Q2W on Days 1 and 15 plus gemcitabine 1000 mg/m2 + nab-paclitaxel 125 mg/m2 on Days 1, 8, and 15 each 28-day cycle.","id":"OG004","title":"TTX-030 (Load+Q2W) + Gemcitabine + Nab-paclitaxel (Days 1, 8, 15)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus budigalimab at a dose of 375 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG005","title":"TTX-030 (Load+Q3W) + Budigalimab (Q3W)"},{"description":"Participants were administered IV TTX-030 at a loading dose of 40 mg/kg 7 days before Cycle 1 Day 1 followed by treatment with 30 mg/kg Q3W plus pembrolizumab at a dose of 200 mg Q3W on Day 1 of each 21-day treatment cycle.","id":"OG006","title":"TTX-030 (Load+Q3W) + Pembrolizumab (Q3W)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Parameters of Serum TTX-030 by Treatment and Visit at C1D1","reportingStatus":"POSTED","timeFrame":"Cycles 1-4 (each cycle is 21-28 days)","title":"Pharmacokinetics (PK)","type":"SECONDARY","unitOfMeasure":"(ug/mL)"}